Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) generates news across animal health, regenerative medicine and veterinary-focused artificial intelligence. The company, together with its subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., reports on developments in its veterinary medical devices, platelet-rich plasma products and AI platforms designed for companion animals and horses.
News coverage for PetVivo often highlights updates on its lead products SPRYNG® with OsteoCushion® technology and PrecisePRP®, including distribution agreements, clinical adoption by veterinary practices and educational initiatives such as continuing education courses and conference presentations. Press releases also describe how these products are promoted through vendor partnerships and distributor networks, as well as their use in managing osteoarthritis, lameness and other joint-related conditions in cats, dogs and horses.
Another key theme in PetVivo news is its expansion into veterinary AI and digital platforms. Announcements have detailed the launch of the PetVivo.ai platform, an AI-powered system intended to improve veterinary client acquisition and engagement through multiple specialized AI agents. Additional releases cover PetVivo’s exclusive 10-year white-label licensing agreement for the Agentic Pet AI framework, publication of a technical whitepaper validating this multi-agent architecture and plans for dual-platform launches that connect pet parents with veterinary practices.
Investors and veterinary professionals following PETV news can also see updates on strategic alliances, board appointments, investor conference presentations and financial results. Earnings-related releases describe revenue trends, product mix developments and distribution expansion, while corporate announcements provide insight into capital structure actions and governance changes. For ongoing context around PetVivo’s products, partnerships and AI initiatives, this news feed offers a centralized view of the company’s public disclosures.
PetVivo Holdings, Inc. will release its financial results for Q2 FY 2022 on November 15, 2021, post-market. A conference call is scheduled for 4:00 p.m. CT to discuss these results. The call will be available via webcast on their Investor Relations website. PetVivo focuses on innovative medical devices for animals, leveraging human therapies to expedite market entry. They have a pipeline of 17 products and 21 patents, with their lead product, SPRYNG™, aimed at treating osteoarthritis in dogs and horses, set for expanded sales this quarter.
PetVivo Holdings, Inc. (NASDAQ: PETV) has appointed Kick as its advertising agency to enhance its branding and marketing strategies. Kick, known for its extensive experience in the animal industry, will assist PetVivo in advertising, digital media, and experiential marketing. CEO John Lai emphasized Kick's strong commitment to impactful messaging and innovative solutions. PetVivo is focused on developing therapeutic devices for animals, notably its flagship product, Spryng with OsteoCushion Technology, aimed at treating osteoarthritis in companion animals, set for expanded commercialization in Q4 2021.
Summary not available.
PetVivo Holdings, Inc. (NASDAQ: PETV) has appointed Joe Manning, DVM, as Senior Technical Veterinarian. Dr. Manning, with over 30 years in the veterinary field, is expected to enhance product development and commercialization of PetVivo's therapeutics for animals. His expertise includes a strong background in marketing and sales for veterinary products. The company aims to leverage human therapies for animal treatment, aiming for accelerated market entry compared to traditional pharmaceuticals. Their lead product, SPRYNG™, will see expanded commercial sales in Q4 2021.
New to The Street will air a special broadcast on September 25, 2021, at 6 PM EDT featuring GlobeX Data (OTCQB:SWISF) and PetVivo (NASDAQ:PETV). The show will reach over 227 million homes across various regions including the US, Latin America, MENA, Asia Pacific, and Australia. Additionally, FMW Media operates one of the longest-running TV brands, enhancing visibility for featured companies. PetVivo focuses on innovative biomedical devices for pets, aiming to leverage advancements from the human medical sector for quicker market entry.
PetVivo Holdings (NASDAQ: PETV) invites investors to its live presentation on September 29, 2021, at the Emerging Growth Conference. The event will feature CEO John Lai discussing the company's innovative medical therapeutics for pets, including their lead product, spryng™ with OsteoCushion™ Technology. Attendees will have the opportunity to ask questions directly during the session starting at 12:00 PM ET. For those unable to attend, an archived webcast will be available later.
PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of Josh Wilhelm as the new Director of Manufacturing. Wilhelm brings expertise in cGMP manufacturing and process engineering, previously serving at the Schulze Diabetes Institute. He aims to enhance the production of spryng, a therapeutic product for treating arthritis in companion animals. The company focuses on innovative medical devices for pets, with a pipeline of 17 products and 21 patents. spryng is expected to expand its commercial availability later this year.
PetVivo Holdings, Inc. (NASDAQ: PETV) announced Mark Middleton as the new National Director of Sales. His 38 years of experience in the Animal Health Industry, including leadership roles at Animal Health International, is expected to enhance sales of PetVivo's spryng™ product, which utilizes OsteoCushion Technology for treating osteoarthritis in pets. The company aims to accelerate revenue generation by leveraging innovative medical therapeutics for companion animals. The lead product is set for expanded commercial sale later this year.
PetVivo Holdings, Inc. (NASDAQ: PETV) will exhibit at the Western Veterinary Conference in Las Vegas from September 6-9, 2021. The company aims to showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for treating joint afflictions in pets. The conference is the largest veterinary event in the Western U.S., attracting over 15,000 participants. PetVivo CEO John Lai expressed optimism about forming industry connections to advance SPRYNG's development and commercialization, with broader sales expected in Q4.
PetVivo Holdings (NASDAQ: PETV) appoints Dr. Ann Zieser as Senior Technical Veterinarian, enhancing the company's veterinary expertise. Dr. Zieser brings over 31 years of experience in veterinary medicine, specializing in companion animal care. She aims to support the introduction of SPRYNG™, a treatment for osteoarthritis in pets, which is set for expanded commercial sales later this year. PetVivo focuses on innovative treatments for companion animals, leveraging human therapies for faster market entry.